Cymbalta “Mood” And “Pain” Claims May Include Fibromyalgia And Anxiety
Executive Summary
Lilly is pursuing fibromyalgia and generalized anxiety disorder indications to add to the two currently approved indications for Cymbalta
You may also be interested in...
Zyprexa Rxs Stabilize, But 2006 Gains Largely Driven By Dual-Eligible Switch
Zyprexa prescription trends are showing signs of stabilization in the U.S., but rebounding sales of Lilly's top-selling drug will be challenged this year as the full-year effect of patient switches from Medicaid to Medicare Part D cycles through in the first quarter, the company said
Zyprexa Rxs Stabilize, But 2006 Gains Largely Driven By Dual-Eligible Switch
Zyprexa prescription trends are showing signs of stabilization in the U.S., but rebounding sales of Lilly's top-selling drug will be challenged this year as the full-year effect of patient switches from Medicaid to Medicare Part D cycles through in the first quarter, the company said
CATIE Suggests Zyprexa Useful As Initial Schizophrenia Treatment – NEJM
Results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study suggest Lilly's Zyprexa may be well suited as initial therapy in the treatment of schizophrenia, according to an editorial accompanying the study